Ann: Commencement Phase 2 Covid-19 Clinical Trial, page-18

Lots of issues with the existing COVID oral treatments....cros reaction with other medications and intolerance. So there remains a window, and while COVID mania has gone it remains a good market as it reverberates particularly if it works on mutations (which it should as it hits the VPN channel. Don't forget the "Spanish flu" didn't get real nasty till 1919 despite having banged around Europe for a year or two on the front lines.
The trials are good news but given the lack of interest by the market I reckon it is positive actual news that will get the market sitting up to notice.